Skip to main content
. 2016 Apr 5;7(22):32286–32305. doi: 10.18632/oncotarget.8591

Figure 8. A model for the effect of miR-K3 on inhibition of KSHV lytic replication and promotion of KSHV-induced angiogenesis and invasion.

Figure 8

Expression of miR-K3 downregulates NFIB, MYB, C/EBPα and Ets-1, which activates the promoter activity of KSHV immediate-early (IE) gene, Rta, resulting in inhibition of viral lytic replication. miR-K3 also directly targets GRK2 promoting cell migration and invasion, and KSHV latency and angiogenesis by activating the CXCR2/AKT pathway.